Hikma Pharmaceuticals (LON:HIK) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Hikma Pharmaceuticals PLC (LON:HIK) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,450.19 and traded as high as GBX 1,496. Hikma Pharmaceuticals shares last traded at GBX 1,475.83, with a volume of 658,113 shares trading hands.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Berenberg Bank restated a “buy” rating and issued a GBX 1,800 target price on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Jefferies Financial Group lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of GBX 2,128.

Hikma Pharmaceuticals Stock Down 0.3%

The company’s 50 day moving average price is GBX 1,416.40 and its 200 day moving average price is GBX 1,448.77. The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 63.59. The firm has a market capitalization of £3.11 billion, a price-to-earnings ratio of 8.08, a P/E/G ratio of 2.38 and a beta of 0.65.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.